Abstract
Sarcoidosis is a multisystem inflammatory disease that commonly affects the lungs, but its precise cause remains unknown. Although mortality is rare, sarcoidosis can cause significant morbidity, including debilitating fatigue and systemic upset, limiting the ability to work or carry out everyday activities. Mild cases may resolve spontaneously and never require treatment, but vital organ involvement is an indication for immunosuppression. The optimal choice of agent and duration of treatment remain unclear. Since sarcoidosis frequently presents to respiratory specialists, they need to be aware of the potential for extra-pulmonary disease and how to recognise it. Diagnosis and management of extra-pulmonary disease requires close collaboration between specialists in different disciplines.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsNotes
- 1.
Typically predominant in the upper zones.
References
Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, et al. Familial aggregation of sarcoidosis: a case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med. 2001;164(11):2085–91.
Scadding JG. Prognosis of intrathoracic sarcoidosis in England. Br Med J. 1961;2:1165–72.
Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305–23.
Lower EE, Harman S, Baughman RP. A randomized, double-blind placebo controlled trial of dexmethylphenidate hydrochloride (d-MPH) for sarcoidosis associated fatigue. Chest. 2008;133:1189–95.
Lower EE, Malhotra A, Surdulescu V, Baughman RP. Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. J Pain Symptom Manag. 2013;45(2):159–69.
Wells AU, Hirani N. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand, and the Irish Thoracic Society. Thorax. 2008;63(Suppl V):v1–58.
Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK, et al. British Thoracic Society Sarcoidosis study: effects of long-term corticosteroid treatment. Thorax. 1996;51(3):238–47.
Cremers JP, Drent M, Bast A, Shigemitsu H, Baughman RP, Valeyre D, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med. 2013;19:545–61.
Müller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14:1117.
British Tuberculosis Association. Chloroquine in the treatment of sarcoidosis. A report from the Research Committee of the British Tuberculosis Association. Tubercle. 1967;48(4):257–72.
Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999;160:192–7.
Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005;127:1064–71.
Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois RM, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795–802.
Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515–26.
Bone and Tooth Society, National Osteoporosis Society, Royal College of Physicians. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: RCP; 2002.
National Institute for Health and Care Excellence. Osteoporosis: assessing the risk of fragility fracture. NICE clinical guideline 146. 2012. Available at: www.nice.org.uk.
Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736–55.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Coker, R.K. (2018). Sarcoidosis. In: Hart, S., Greenstone, M. (eds) Foundations of Respiratory Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-94127-1_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-94127-1_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-94125-7
Online ISBN: 978-3-319-94127-1
eBook Packages: MedicineMedicine (R0)